Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine
Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine
复制标题
与替比夫定相关的肌酸激酶升高的累积发生率和危险因素。
DOI：
10.1007/s00228-015-1978-9
复制
发表时间：
2016-02-01
影响因子：
2.9
通讯作者：
Wang, Bin
中科院分区：
文献类型：
--
作者：
Chen, Li;Cheng, Cai;Wang, Bin
An increasing number of studies are reporting a high frequency of creatine kinase (CK) elevation during telbivudine therapy; however, few reports have focused on the cumulative incidence and risk factors of CK elevation. This study was performed to investigate the cumulative incidence and risk factors of CK elevation in Chinese patients treated with telbivudine.In this observational study, patients with chronic hepatitis B receiving telbivudine therapy between July 2008 and December 2013 were enrolled. The cumulative incidence of CK elevation was analyzed using the Kaplan-Meier method combined with the log rank test. Risk factors were determined using Cox proportional hazards regression models.A total of 207 eligible patients were analyzed. The cumulative incidence of CK elevation at 12, 24, 36, 48, 60, and 72 months was 51.2 %, 68.9 %, 75.1 %, 78.1 %, 78.1 %, and 78.1 %, respectively. Multivariate analysis revealed that male and lower baseline estimated glomerular filtration rate (eGFR) were significant risk factors for CK elevation.The cumulative incidence of CK elevation after long-term telbivudine use is quite high, and gender and baseline eGFR may be useful predictors. However, when combined with regular monitoring of CK levels, especially for patients with lower eGFR, telbivudine is a relatively safe nucleoside analog treatment for chronic hepatitis B.
